Joachim Almquist
Research Subjects
Joachim Almquist has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Raj Tummala
BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USA
2 shared publications - Weifeng Tang
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Gaithersburg Maryland USA
2 shared publications Alexander MacDonald
Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK
1 shared publication- Anna Lundahl
Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences R&D, AstraZeneca Gothenburg Sweden
1 shared publication - Anne-Kristina Mercier
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden
1 shared publication Carol Astbury
Projects Department, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Cambridge UK
1 shared publication
Latest Publications
- Open Access
From exact gradients to exact standard errors: third- and fourth-order sensitivities for the Laplacian population likelihood family
Asymptotic standard errors for the parameters of a nonlinear mixed effects model fitted by Laplacian estimation, first-order conditional estimation (FOCE), or FOCE with interaction (FOCEI) require the observed (Fisher) information, the negative second derivative of the population objective at the optimum. The gradient of this objective can be computed exactly from sensitivity equations, but the observed information is still formed by finite differencing, which is less accurate, step-size dependent, and requires empirical Bayes reoptimization. These perturbed individual optimization problems can fail even after a successful fit. Our objectives are to (1) extend the exact-gradient sensitivity framework by one differentiation and give the observed information of the Laplacian population likelihood family in closed form and (2) illustrate covariance calculation without further empirical Bayes optimization in a case example. Writing the objective as a data term plus the log-determinant of the inner Hessian, the population Hessian splits so that the data term reuses second-order sensitivities, whereas the log determinant term requires third-order sensitivities for FOCE/FOCEI and fourth-order sensitivities for the full Laplacian method. We illustrate this on a two-compartment oral model with first-order absorption fitted to simulated data. The analytic covariance involves no differencing step and uses the fitted empirical Bayes estimates without reoptimization, avoiding this source of covariance-step failure. Implemented for FOCE/FOCEI in the open-source R package nlmixr2, the construction provides exact, reproducible standard errors for the approximate likelihood, limited by numerical solution accuracy and conditioning. This supports more dependable confidence intervals, identifiability assessment, and uncertainty propagation.
Open AccessFrom exact gradients to exact standard errors: third- and fourth-order sensitivities for the Laplacian population likelihood family
Asymptotic standard errors for the parameters of a nonlinear mixed effects model fitted by Laplacian estimation, first-order conditional estimation (FOCE), or FOCE with interaction (FOCEI) require the observed (Fisher) information, the negative second derivative of the population objective at the optimum. The gradient of this objective can be computed exactly from sensitivity equations, but the observed information is still formed by finite differencing, which is less accurate, step-size dependent, and requires empirical Bayes reoptimization. These perturbed individual optimization problems can fail even after a successful fit. Our objectives are to (1) extend the exact-gradient sensitivity framework by one differentiation and give the observed information of the Laplacian population likelihood family in closed form and (2) illustrate covariance calculation without further empirical Bayes optimization in a case example. Writing the objective as a data term plus the log-determinant of the inner Hessian, the population Hessian splits so that the data term reuses second-order sensitivities, whereas the log determinant term requires third-order sensitivities for FOCE/FOCEI and fourth-order sensitivities for the full Laplacian method. We illustrate this on a two-compartment oral model with first-order absorption fitted to simulated data. The analytic covariance involves no differencing step and uses the fitted empirical Bayes estimates without reoptimization, avoiding this source of covariance-step failure. Implemented for FOCE/FOCEI in the open-source R package nlmixr2, the construction provides exact, reproducible standard errors for the approximate likelihood, limited by numerical solution accuracy and conditioning. This supports more dependable confidence intervals, identifiability assessment, and uncertainty propagation.
- Open Access
- 22 May 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (2) , 429-439
Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis
In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE. In a phase 2 trial in patients with LN (TULIP‐LN; NCT02547922), promising clinical benefit was observed with an intensified regimen (IR) of intravenous anifrolumab (3× 900 mg Q4W, 300 mg thereafter) compared with the approved SLE dose (basic regimen [BR], 300 mg Q4W). Anifrolumab clearance was greater with higher levels of proteinuria; however, the quantitative relationship between proteinuria and anifrolumab exposure was not fully characterized. Here, we describe a mathematical model of time‐varying anifrolumab pharmacokinetics, 24‐hour urine protein–creatinine ratio (UPCR24), and investigational product discontinuation in patients with LN. The model evaluated both TULIP‐LN anifrolumab dosing regimens (IR and BR) and revealed a temporal association between clearance and proteinuria in patients with LN, with each mg/mg UPCR reduction resulting in a 21% decrease in linear anifrolumab clearance. Our model indicated that an intensified regimen including 6 initial anifrolumab 900 mg doses provided adequate exposure and rapid UPCR24 reduction. Higher anifrolumab exposure and reduced UPCR24 were each associated with decreased risk of treatment discontinuation. These model results guided the selection of an optimized, longer intensified anifrolumab dosing regimen (6× 900 mg Q4W, 300 mg thereafter) for the ongoing phase 3 IRIS trial (NCT05138133).
- 22 May 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (2) , 429-439
Open AccessAnifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis
In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE. In a phase 2 trial in patients with LN (TULIP‐LN; NCT02547922), promising clinical benefit was observed with an intensified regimen (IR) of intravenous anifrolumab (3× 900 mg Q4W, 300 mg thereafter) compared with the approved SLE dose (basic regimen [BR], 300 mg Q4W). Anifrolumab clearance was greater with higher levels of proteinuria; however, the quantitative relationship between proteinuria and anifrolumab exposure was not fully characterized. Here, we describe a mathematical model of time‐varying anifrolumab pharmacokinetics, 24‐hour urine protein–creatinine ratio (UPCR24), and investigational product discontinuation in patients with LN. The model evaluated both TULIP‐LN anifrolumab dosing regimens (IR and BR) and revealed a temporal association between clearance and proteinuria in patients with LN, with each mg/mg UPCR reduction resulting in a 21% decrease in linear anifrolumab clearance. Our model indicated that an intensified regimen including 6 initial anifrolumab 900 mg doses provided adequate exposure and rapid UPCR24 reduction. Higher anifrolumab exposure and reduced UPCR24 were each associated with decreased risk of treatment discontinuation. These model results guided the selection of an optimized, longer intensified anifrolumab dosing regimen (6× 900 mg Q4W, 300 mg thereafter) for the ongoing phase 3 IRIS trial (NCT05138133).
- Open Access
- 30 August 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (1) , 257-268
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma
Aims: Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a novel JAK1 selective inhibitor, following inhaled (dry powder, nebulized) and intravenous administration to healthy participants and patients with mild asthma. Methods: This was a randomized, single‐blind, placebo‐controlled Phase 1 study (NCT03766399) of single‐ and multiple‐ascending doses conducted using a three‐part design. Healthy participants and patients with mild asthma aged 18–55 years were recruited. The study evaluated safety, tolerability, PK and PD of AZD0449. PD was measured as the effect on fractional exhaled nitric oxide (FeNO). Systemic target engagement was measured using phosphorylation of signal transducer and activator of transcription 6 (pSTAT6). Results: A total of 125 participants were included in the study. No drug‐related safety concerns emerged. Following inhaled administration, AZD0449 showed low, dose‐proportional, systemic exposures and elimination from plasma was partly absorption‐limited, suggesting lung retention and supporting once‐daily dosing. At the dose levels evaluated (1.2–5.0 mg), there was no significant anti‐inflammatory effect (reduction in FeNO) with AZD0449 vs . placebo, following repeated dosing for 14 days. Furthermore, there was no significant suppression of pSTAT6. Conclusions: AZD0449 was safely administered via inhalation, with low systemic exposure and lung retention. This study provides a greater understanding of inhaled dosing of small molecule JAK1 inhibitors for the treatment of asthma. No effect on PD biomarkers (FeNO and STAT6) was observed.
- 30 August 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (1) , 257-268
Open AccessAZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma
Aims: Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a novel JAK1 selective inhibitor, following inhaled (dry powder, nebulized) and intravenous administration to healthy participants and patients with mild asthma. Methods: This was a randomized, single‐blind, placebo‐controlled Phase 1 study (NCT03766399) of single‐ and multiple‐ascending doses conducted using a three‐part design. Healthy participants and patients with mild asthma aged 18–55 years were recruited. The study evaluated safety, tolerability, PK and PD of AZD0449. PD was measured as the effect on fractional exhaled nitric oxide (FeNO). Systemic target engagement was measured using phosphorylation of signal transducer and activator of transcription 6 (pSTAT6). Results: A total of 125 participants were included in the study. No drug‐related safety concerns emerged. Following inhaled administration, AZD0449 showed low, dose‐proportional, systemic exposures and elimination from plasma was partly absorption‐limited, suggesting lung retention and supporting once‐daily dosing. At the dose levels evaluated (1.2–5.0 mg), there was no significant anti‐inflammatory effect (reduction in FeNO) with AZD0449 vs . placebo, following repeated dosing for 14 days. Furthermore, there was no significant suppression of pSTAT6. Conclusions: AZD0449 was safely administered via inhalation, with low systemic exposure and lung retention. This study provides a greater understanding of inhaled dosing of small molecule JAK1 inhibitors for the treatment of asthma. No effect on PD biomarkers (FeNO and STAT6) was observed.
- 1 May 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (8) , 1921-1931
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial
Aims: Corticosteroids are the treatment of choice for many inflammatory diseases but often lead to adverse effects, including hyperglycaemia. This study investigated the mechanisms driving differential effects on glucose control for AZD9567, an oral nonsteroidal selective glucocorticoid receptor modulator vs. prednisolone in 46 patients with type 2 diabetes mellitus.Methods: In this randomized, double‐blind, 2‐way cross‐over study (NCT04556760), participants received either AZD9567 72 mg and prednisolone 40 mg daily (cohort 1); AZD9567 40 mg and prednisolone 20 mg daily (cohort 2); or placebo and prednisolone 5 mg daily (cohort 3). Treatment duration was 3 days with a 3‐week washout between treatment periods. Glycaemic control was assessed after a standardized meal and with continuous glucose monitoring.Results: A significant difference between AZD9567 and prednisolone in favour of AZD9567 was observed for the change from baseline to Day 4 glucose excursions postmeal in cohort 1 (glucose area under the curve from 0 to 4 h −4.54%; 95% confidence interval [CI]: −8.88, −0.01; P = .049), but not in cohort 2 (−5.77%; 95% CI: −20.92, 12.29; P = .435). In cohort 1, significant differences between AZD9567 and prednisolone were also seen for the change from baseline to day 4 in insulin and glucagon secretion postmeal (P < .001 and P = .005, respectively) and change from baseline to Day 4 in GLP‐1 response (P = .022). Significant differences between AZD9567 and prednisolone for 24‐h glucose control were observed for both cohort 1 (−1.507 mmol/L; 95% CI: −2.0820, −0.9314; P < .001) and cohort 2 (−1.110 mmol/L; 95% CI −1.7257, −0.4941; P < .001).Conclusion: AZD9567 significantly reduced treatment‐induced hyperglycaemia compared with prednisolone.
- 1 May 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (8) , 1921-1931
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial
Aims: Corticosteroids are the treatment of choice for many inflammatory diseases but often lead to adverse effects, including hyperglycaemia. This study investigated the mechanisms driving differential effects on glucose control for AZD9567, an oral nonsteroidal selective glucocorticoid receptor modulator vs. prednisolone in 46 patients with type 2 diabetes mellitus.Methods: In this randomized, double‐blind, 2‐way cross‐over study (NCT04556760), participants received either AZD9567 72 mg and prednisolone 40 mg daily (cohort 1); AZD9567 40 mg and prednisolone 20 mg daily (cohort 2); or placebo and prednisolone 5 mg daily (cohort 3). Treatment duration was 3 days with a 3‐week washout between treatment periods. Glycaemic control was assessed after a standardized meal and with continuous glucose monitoring.Results: A significant difference between AZD9567 and prednisolone in favour of AZD9567 was observed for the change from baseline to Day 4 glucose excursions postmeal in cohort 1 (glucose area under the curve from 0 to 4 h −4.54%; 95% confidence interval [CI]: −8.88, −0.01; P = .049), but not in cohort 2 (−5.77%; 95% CI: −20.92, 12.29; P = .435). In cohort 1, significant differences between AZD9567 and prednisolone were also seen for the change from baseline to day 4 in insulin and glucagon secretion postmeal (P < .001 and P = .005, respectively) and change from baseline to Day 4 in GLP‐1 response (P = .022). Significant differences between AZD9567 and prednisolone for 24‐h glucose control were observed for both cohort 1 (−1.507 mmol/L; 95% CI: −2.0820, −0.9314; P < .001) and cohort 2 (−1.110 mmol/L; 95% CI −1.7257, −0.4941; P < .001).Conclusion: AZD9567 significantly reduced treatment‐induced hyperglycaemia compared with prednisolone.
- Open Access
- 6 May 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (5) , 655-671
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
The type I interferon (IFN) signaling pathway is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab is a monoclonal antibody that targets the type I IFN receptor subunit 1. Anifrolumab is approved in several countries for patients with moderate to severe SLE receiving standard therapy. The approved dosing regimen of anifrolumab is a 300-mg dose administered intravenously every 4 weeks; this was initially based on the results of the Phase 2b MUSE and further confirmed in the Phase 3 TULIP-1 and TULIP-2 trials, in which anifrolumab 300-mg treatment was associated with clinically meaningful improvements in disease activity with an acceptable safety profile. There have been several published analyses of the pharmacokinetic and pharmacodynamic profile of anifrolumab, including a population–pharmacokinetic analysis of 5 clinical studies of healthy volunteers and patients with SLE, in which body weight and type I IFN gene expression were significant covariates identified for anifrolumab exposure and clearance. Additionally, the pooled Phase 3 SLE population has been used to evaluate how serum exposure may be related to clinical responses, safety risks, and pharmacodynamic effects of the 21-gene type I IFN gene signature (21-IFNGS). The relevance of 21-IFNGS with regard to clinical efficacy outcomes has also been analyzed. Herein, the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of anifrolumab as well as results of population–pharmacokinetics and exposure–response analyses are reviewed.
- 6 May 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (5) , 655-671
Open AccessClinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
The type I interferon (IFN) signaling pathway is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab is a monoclonal antibody that targets the type I IFN receptor subunit 1. Anifrolumab is approved in several countries for patients with moderate to severe SLE receiving standard therapy. The approved dosing regimen of anifrolumab is a 300-mg dose administered intravenously every 4 weeks; this was initially based on the results of the Phase 2b MUSE and further confirmed in the Phase 3 TULIP-1 and TULIP-2 trials, in which anifrolumab 300-mg treatment was associated with clinically meaningful improvements in disease activity with an acceptable safety profile. There have been several published analyses of the pharmacokinetic and pharmacodynamic profile of anifrolumab, including a population–pharmacokinetic analysis of 5 clinical studies of healthy volunteers and patients with SLE, in which body weight and type I IFN gene expression were significant covariates identified for anifrolumab exposure and clearance. Additionally, the pooled Phase 3 SLE population has been used to evaluate how serum exposure may be related to clinical responses, safety risks, and pharmacodynamic effects of the 21-gene type I IFN gene signature (21-IFNGS). The relevance of 21-IFNGS with regard to clinical efficacy outcomes has also been analyzed. Herein, the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of anifrolumab as well as results of population–pharmacokinetics and exposure–response analyses are reviewed.